Watchlist
By the TelehealthIndex Editorial Team · Below are companies we researched and do not currently rank, companies that have shut down or left the consumer market, and cases we are still reviewing — with the documented reasons for each. Ranking a provider is a decision; so is declining to. These reflect our editorial assessment of public records as of July 19, 2026; we correct promptly if the record changes. Dispute an entry →
Not currently ranked
Companies we researched and decline to rank under our methodology, based on our editorial assessment of public records.
Eli Lilly false-advertising suit allowed to proceed (2026); WA State investigation of its Aequita pharmacy (contamination reports, license restricted Feb 2026); BBB D+ reported.
Confirmed FDA warning letter June 8, 2026 (#728279) over compounded GLP-1 marketing.
Source: FDA Warning Letter to Eden Health International Inc. dba Eden, No. 728279 (June 8, 2026)
Compounded-only GLP-1 model; Eli Lilly suit proceeding; consumer class actions.
Trustpilot 2.2 (Poor), BBB F unresponsive, cherry-picked owned reviews. Has affiliate program (in-house + CJ) - excluded anyway; monetization does not override credibility.
FDA warning letter No. 721448 (Feb 20, 2026) ('generic Zepbound' claims); compounded-ED specialist. Possible future 'budget option' mention with prominent disclosure only.
Source: FDA Warning Letter to Strut Health, LLC dba Strut, No. 721448 (Feb 20, 2026)
TINA.org hidden-fee advertising alert Dec 2024.
No verifiable track record.
June 2026 $3.325M DOJ False Claims Act settlement (NP/PA supervision); CVS refuses its controlled-substance scripts; ADHD-stimulant model exposed to Dec 31, 2026 DEA flexibility expiration.
Bloomberg 'IVF Disrupted' investigation (embryo errors), valuation collapse $1.8B to ~$400M, clinic closures, executive churn.
Ranked with a Caution notice
These do appear in our rankings, held at their computed score with a visible Caution notice — never hidden, never promoted above their rank.
Ranked with Caution banner per methodology gate - confirmed FDA warning letter Sept 2025, transition to brand-only in progress.
Ranked but with prominent enforcement-history disclosure per methodology (FTC 2024 order, DOJ NPA 2024, 3.18M-person pixel breach).
No longer operating for consumers
Direct-to-consumer service discontinued or the company has shut down.
Shut down direct-to-consumer platform Dec 31, 2025; now B2B-only powering health-system virtual care.
Exited consumer TRT; now workforce screening (Sterling/First Advantage).
Shut down by Hims & Hers March 7, 2025; derm folded into core platform.
Under review or not yet rankable
Borderline cases we are re-evaluating, or products not yet generally available to consumers.
Borderline: cheap ($79/mo), LegitScript seal, strong Trustpilot, but BBB F with unanswered complaints. Re-evaluate next cycle. Has in-house affiliate program.
Primarily B2B employer benefit; consumer product in waitlisted beta (Mar 2026), unpublished pricing. Revisit when generally available.
Statements about enforcement actions, litigation, and business status describe public records and reporting as of July 19, 2026 and are our editorial summary, not legal conclusions. A company that believes an entry is inaccurate may write to corrections@telehealthindex.com; disputes are resolved against primary sources.